Evaluación de ELISA F29 como marcador de eficacia del tratamiento etiológico en la enfermedad de Chagas

Fabbro, Diana Lucrecia; Velázquez, Elsa; Mendoza, Norberto; Streiger, Mirtha; Arias, Enrique; Denner, Susana; Barco, Mónica del; Amicone, Norberto A.; Pravia, Carlos; Malagrino, Nora; Ruiz, Andrés M.

doi:10.4067/s0717-77122007000200001

Cited by 7 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-cruzipain antibody levels were detectable in both infected and infected-treated mice up to 90 days postinfection. A longer period of time is probably necessary to reverse the serology response, as has been demonstrated by other authors finding that parasite antigens persist for long periods in the infected host, even when parasitemia has been negativized by the treatment (Fabbro et al 2007).…”

Section: Discussionmentioning

confidence: 81%

Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi

et al. 2010

View full text Add to dashboard Cite

We have previously shown that clomipramine and allopurinol used separately are effective in preventing chronic chagasic cardiomyopathy. The aim of the present study was to evaluate the effect of the association of clomipramine (Clo--5 mg/kg/day/90 days) and allopurinol (Allo--5, 10, or 15 mg/kg/day/90 days) for the treatment of experimental Chagas disease in the acute stage. Treatment effectiveness was evaluated through parasitemia, survival, electrocardiography, serology, and cardiac histopathology. Groups treated showed no electrocardiographic abnormalities, in contrast to those untreated which presented 25% of mice with conduction alterations. The myocardium of treated mice (Clo, Allo10+Clo, and Allo15+Clo) presented no structural alterations. Cardiac b-receptor affinity was preserved in mice treated with Clo or Clo+Allo at the different doses; receptor density of the Clo and Allo15+Clo groups did not differ from the non-infected group. Anti-cruzipain antibody levels were similar in treated and untreated groups. Survival was significantly increased in the treated groups (p < 0.05), with Clo and all the Clo+Allo groups presenting the highest rates. These results show that the association of clomipramine + allopurinol is effective for Chagas disease treatment and has the same effect as clomipramine alone.

show abstract

Section: Discussionmentioning

confidence: 81%

Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi

et al. 2010

View full text Add to dashboard Cite

show abstract

“…However, the antibody titres remained positive; this has to be attributed to the partial elimination of T. cruzi in the treated subjects discussed before. Other studies have found that parasite antigens persist for long periods in infected individuals, even after the parasitaemia load was reduced by the treatment (Fabro et al 2007). This has also been found for benznidazole, nifurtimox or allopurinol tests, where the serology was positive many years after the treatment started (Segura et al 1996).…”

Section: Discussionmentioning

confidence: 97%

Use of clomipramine as chemotherapy of the chronic phase of Chagas disease

et al. 2013

View full text Add to dashboard Cite

Chagas infection is a major endemic disease affecting Latin American countries. The persistence of Trypanosoma cruzi generates a chronic inflammatory reactivity that induces an immune response directed to the host's tissues. The effectiveness of the treatment in the chronic phase is still unsatisfactory due, amongst other reasons, to the collateral effects of the drugs used. We investigated the effect of clomipramine, a tricyclic antidepressant that, when used as a treatment of T. cruzi-chronically infected mice, inhibits trypanothione reductase, an exclusive and vital enzyme of T. cruzi. Clomipramine improved survival (P<0.05) by diminishing the parasite intensity as demonstrated by PCR studies in the heart and skeletal muscle, and significantly prevented the evolution to fibrosis of the inflammatory infiltrates. Clomipramine could be a good candidate for the treatment of chronic Chagas disease.

show abstract

“…Similar results were observed in several previous clinical studies. In a retrospective cross-sectional study, for example, serum samples from patients with chronic Chagas disease (n = 118) followed for up to 23 years and either treated with trypanocidal therapy (nifurtimox or benznidazole) or left untreated were evaluated by ELISA F29, and its relation to conventional serology, blood parasite levels evaluated by xenodiagnosis, and clinical aspects were analyzed [ 11 ]. ELISA F29 was nonreactive in all patients who showed negative conventional serology after treatment (n = 30), in 82.4% of treated patients but who remained reactive by conventional serology (n = 34), and in 13% of the untreated patients (n = 54).…”

Section: Discussionmentioning

confidence: 99%

“…An ELISA containing a recombinant 29 kDa T . cruzi calcium-binding protein as antigen was used to analyze serum samples taken from pediatric patients, as previously described [ 11 ]. The purified protein was resuspended in carbonate buffer pH 9.6 at a concentration of 5 μg/ml and dispensed to 96-well polystyrene plates at a final volume of 50 μl per well and fixed overnight at 4°C.…”

Section: Methodsmentioning

confidence: 99%

“…Potential biomarkers of early therapeutic responses have been tested in different clinical contexts. An ELISA using a 29 kDa flagellar recombinant F29 antigen of the parasite (ELISA F29) was developed [ 9 ], which has been successfully assessed as an early biomarker of response to treatment with benznidazole in children [ 10 ] and in children and adults treated with antitrypanosomal therapy [ 11 , 12 ]. Significant differences in the reactivity towards F29 were observed between treated and untreated patients, and ELISA F29 is proposed as a useful method to monitor the response to drug treatment [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment

et al. 2023

View full text Add to dashboard Cite

Background Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administered by two different treatment regimens on the T. cruzi calcium-binding flagellar protein F29 in children diagnosed with Chagas disease measured using an enzyme-linked immunosorbent assay (ELISA) technique (ELISA F29). Methods and principal findings In a phase 3, randomized, double-blind, parallel-group, historically controlled study (ClinicalTrials.gov NCT02625974), blood samples obtained from children diagnosed with Chagas disease and treated with nifurtimox for either 60 days or 30 days were analyzed using an ELISA with an F29 recombinant protein as the antigen, as well as conventional serological tests (recombinant ELISA and indirect hemagglutination assay). In an exploratory approach, serological response to nifurtimox treatment was evaluated for 4 years post-treatment. In both treatment groups, the number of patients with negative ELISA F29 values increased over the period of observation. The incidence rate of negative seroconversion using ELISA F29 was 22.94% (95% CI: 19.65%, 26.63%) in the 60-day treatment group and 21.64% (95% CI: 17.21%, 26.86%) in the 30-day treatment group. In the subpopulation of patients who tested seropositive for F29 before nifurtimox treatment, 88 patients (67.7%) in the 60-day regimen and 39 patients (59.1%) in the 30-day regimen were F29 seronegative at 4 years post-treatment. All patients who had a positive ELISA F29 test at baseline and seroconverted to negative measured by conventional serology reached seronegativity in ELISA F29 earlier than in conventional serology. Conclusions The results demonstrate a serological response to treatment with nifurtimox measured by the ELISA F29 test in children diagnosed with Chagas disease. The F29-based ELISA can be considered a potential early marker of response to antitrypanosomal therapy for Chagas disease. Trial registration ClinicalTrials.gov NCT02625974.

show abstract

Evaluación de ELISA F29 como marcador de eficacia del tratamiento etiológico en la enfermedad de Chagas

Abstract: A transversal study was performed on sera from chronic chagasic patients treated with nifurtimox (Nx)

Cited by 7 publications

References 13 publications

Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi

Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi

Use of clomipramine as chemotherapy of the chronic phase of Chagas disease

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment

Contact Info

Product

Resources

About